label int64 1 1 | id stringlengths 10 12 | original_id stringlengths 8 9 | text stringlengths 347 29.5k |
|---|---|---|---|
1 | 172424023_b0 | 172424023 | .0
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of Rigs Purchased at Auction | drilling_unit
2
P-59 and P60 Rigs [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Purchase Price of Rigs Won at Auction
77.0
P-60 [Member] | Subsequent Event [Member]
Subsequent Event [Line Item... |
1 | 172424023_b1 | 172424023 | .6) 262.4 457.4 719.8
(80.9) 37.5 481.3 (540.1) (49.0)
0.0
(151.2) 212.7 244.7 457.4
$ 0.0 $ 0.0 $ 0.0
RELATED PARTIES (Details) - Schlumberger
[Member] - USD ($) $ in Millions
12 Months Ended Dec. 31, 2017 Dec. 31, 2016
Related Party Transaction [Line Items]
Related party purchases
$ 20.9
$ 28.4
Accounts Pay... |
1 | 172425227_0 | 172425227 | Clementia Pharmaceuticals Inc.
Form 20-F
Filed on 28-Feb-2018 Period 31-Dec-2017 Accession number: 0001171843-18-001547
Included Items
1. 20-F: FORM 20-F 2. EX-12.1: EXHIBIT 12.1 3. EX-12.2: EXHIBIT 12.2 4. EX-13.1: EXHIBIT 13.1 5. EX-13.2: EXHIBIT 13.2 6. EX-23.1: EXHIBIT 23.1 7. XBRL (render)
UNITED STATES SECURI... |
1 | 172425227_1 | 172425227 | SUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 For the transition period from to
OR ¨ SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 Date of event requiring this shell company report
Commission file number 001-38177
CLEMENTIA PHARMACEUTICALS INC.
(Exact nam... |
1 | 172425227_2 | 172425227 | each class Common Shares, no par value
Name of each exchange on which registered The Nasdaq Global Select Market
Securities registered or to be registered pursuant to Section 12(g) of the Act: None (Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None (Titl... |
1 | 172425227_3 | 172425227 | .
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing require... |
1 | 172425227_b0 | 172425227 | Financial Instruments - Exposed to Currency Risk (Details)
Dec. 31, 2017 Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2016 Dec. 31, 2015 Dec. 31, 2015
CAD
EUR ()
CAD
EUR ()
CAD
EUR ()
Statement Line Items [Line Items]
Cash
CAD 954,965 139,056 CAD 931,082 63,033 CAD 4,328,341 98,060
Interest, sales tax and other ... |
1 | 172425227_b1 | 172425227 | of Key Management Personnel (Details) - USD ($)
12 Months Ended Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2015
Statement Line Items [Line Items]
Short-term benefits
$ 2,176,345 $ 1,742,021 $ 1,672,327
Director fees
116,398 45,540
46,920
Short-termbenefits and director fees 2,292,743 1,787,561 1,719,247
Stock-based ... |
1 | 172426847_0 | 172426847 | Medidata Solutions, Inc.
Form 10-K
Filed on 28-Feb-2018 Period 31-Dec-2017 Accession number: 0001453814-18-000052
Included Items
1. 10-K: FORM 10-K 2. EX-10.16: EXHIBIT 10.16 3. EX-21.1: SUBSIDIARIES OF MEDIDATA
SOLUTIONS, INC. 4. EX-23.1: CONSENT OF DELOITTE & TOUCHE
LLP 5. EX-31.1: CERTIFICATION OF CEO PURSUANT
TO ... |
1 | 172426847_1 | 172426847 | 14(B) OR 15D-14(B) 9. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________
FORM 10-K
_____________________________________
ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal ye... |
1 | 172426847_2 | 172426847 | 's telephone number, including area code)
Securities registered under Section 12(b) of the Exchange Act:
Title of each class
Name of each exchange on which registered
Common Stock, par value $0.01 per share
The NASDAQ Stock Market LLC
Securities registered under Section 12(g) of the Exchange Act: None
Indicate by... |
1 | 172426847_3 | 172426847 | everyInteractive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ý Yes ¨ No
Indicate bycheck mark if disclosure of delinquent fil... |
1 | 172426847_b0 | 172426847 |
Information [Abstract]
Total revenues
$
$
$
$
$
$
$
$
$
$
$
141,217 140,080 137,414 126,821 124,472 120,061 114,610 104,238 545,532 463,381 392,506
Gross profit
108,512 108,526 105,494 96,207 94,816 90,833 85,553 79,570 418,739 350,772 302,718
Operating income
16,472 21,960 13,743 12,173 17,498 14,92... |
1 | 172426847_b1 | 172426847 | ed equity awards, unless otherwise specified in the equity award agreements.
Wire transaction claim description
In September 2014, the Company discovered that it had been the victim of a crime involving the fraudulently induced transfer of $4.8 million. The Company filed an insurance claim for its loss, and its insur... |
1 | 172432427_0 | 172432427 | Criteo S.A.
Form 10-K
Filed on 01-Mar-2018 Period 31-Dec-2017 Accession number: 0001576427-18-000008
Included Items
1. 10-K 2. EX-4.3: EXHIBIT 4.3 3. EX-21.1: EXHIBIT 21.1 4. EX-23.1: EXHIBIT 23.1 5. EX-31.1: EXHIBIT 31.1 6. EX-31.2: EXHIBIT 31.2 7. EX-32.1: EXHIBIT 32.1 8. XBRL (render)
UNITED STATES SECURITIES AN... |
1 | 172432427_1 | 172432427 | 1934
for the transition period from
to
Commission file number: 001-36153
Criteo S.A. (Exact name of registrant as specified in its charter)
France (State or other jurisdiction of incorporation or
organization)
Not Applicable (I.R.S. Employer Identification Number)
32, rue Blanche, 75009 Paris--France (Address o... |
1 | 172432427_2 | 172432427 | of the Securities Act. Yes x No ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of... |
1 | 172432427_3 | 172432427 | or any amendment to this Form 10-K. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"... |
1 | 172432427_b0 | 172432427 | 1,799,146 $ 1,323,169
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
869,004 630,047 419,742
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
183,297 137,116 111,792
United Kingdom
Revenues from External Customers and Long-Lived As... |
1 | 172432427_b1 | 172432427 |
Asia-Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
$ 497,307 $ 407,750 $ 276,411
Breakdown of Revenue and Non-Current Assets by Geographical Areas -
Narrative (Details) - USD ($) $ in Thousands
12 Months Ended Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2015
Revenues from Externa... |
1 | 172432453_0 | 172432453 | PERRIGO Co Plc
Form 10-K
Filed on 01-Mar-2018 Period 31-Dec-2017 Accession number: 0001585364-18-000015
Included Items
1. 10-K 2. EX-10.61: EXHIBIT 10.61 3. EX-10.62: EXHIBIT 10.62 4. EX-10.63: EXHIBIT 10.63 5. EX-10.68: EXHIBIT 10.68 6. EX-10.69: EXHIBIT 10.69 7. EX-21: EXHIBIT 21 8. EX-23: EXHIBIT 23 9. EX-31: EXHI... |
1 | 172432453_1 | 172432453 | SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____
Commission file number 001-36353
Perrigo Company plc
(Exact name of registrant as specified in its charter)
Ireland (State or other jurisdiction of incorporation or organization)
N/A (I.R.S. Employer Identificati... |
1 | 172432453_2 | 172432453 | Section 15(d) of the Act.
YES
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been... |
1 | 172432453_3 | 172432453 | this Form10-K.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth... |
1 | 172432453_b0 | 172432453 | , and loss on early debt extinguishment of $135.2 million. [4] Includes IPR&D impairment charges of $12.2 million, gain on certain divestiture of $21.8 million, and restructuring charges of $38.7 million. [5] Includes intangible asset impairment charges of $378.6 million, goodwill impairment charge of $224.1 million, a... |
1 | 172432453_b1 | 172432453 | SecondQuarter (3) ThirdQuarter (4) FourthQuarter (5)Net sales$1,347.3 $1,340.5 $1,261.6 $1,331.2Gross profit$533.1 $546.5 $484.5 $487.7Change in financial assets$204.4 $910.8 $377.4 $1,115.6Net loss$(529.2) $(534.3) $(1,590.2) $(1,359.1)Loss per share(1): Basic$(3.70) $(3.73) $(11.10) $(9.48)Diluted$(3.70) $(3.73) $(1... |
1 | 172435730_0 | 172435730 | Ardagh Group S.A.
Form 20-F
Filed on 02-Mar-2018 Period 31-Dec-2017 Accession number: 0001558370-18-001460
Included Items
1. 20-F 2. EX-12.1 3. EX-12.2 4. EX-13.1 5. EX-13.2 6. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549
FORM 20-F ANNUAL REPORT OF FOREIGN PRIVATEISSUER
PURSU... |
1 | 172435730_1 | 172435730 | on which registered
Class A Common Shares, par value 0.01 per share
New York Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None
Indicate the number of outstanding shar... |
1 | 172435730_2 | 172435730 | for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the
past 90 days.
Yes No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File requi... |
1 | 172435730_3 | 172435730 |
International Financial Reporting Standards
Other
as issued by the International Accounting
Standards Board
If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
Item 17 __ Item 18__
If this is an annual re... |
1 | 172435730_b0 | 172435730 | borrowings
Borrowings
0
673
Ardagh Group S.A. | Later than five years
Maturity analysis of borrowings including related party borrowings
Borrowings
673
Company financial
12 Months Ended
information - Distributions
paid and received and
commitments and contingencies (Details) - EUR Dec. 31, 2017 Dec. 31,... |
1 | 172435730_b1 | 172435730 | equivalents
1
(2)
Cash and cash equivalents at the beginning of the year
2
2
Cash and cash equivalents at the end of the year
1
2
Company financial information - Maturity analysis of borrowings
(Details) - EUR () in Millions
Dec. 31, 2017 Dec. 31, 2016
Maturity analysis of borrowings including related ... |
1 | 172439318_0 | 172439318 | Talend SA
Form 20-F
Filed on 05-Mar-2018 Period 31-Dec-2017 Accession number: 0001668105-18-000005
Included Items
1. 20-F 2. EX-1.1 3. EX-4.12 4. EX-4.23 5. EX-4.24 6. EX-4.25 7. EX-4.26 8. EX-4.27 9. EX-4.6 10. EX-8.1 11. EX-12.1 12. EX-12.2 13. EX-13.1 14. EX-15.1 15. XBRL (render)
Table of Contents
UNITED STATE... |
1 | 172439318_1 | 172439318 | ended December 31, 2017 OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR15(d) OF THESECURITIES EXCHANGEACT OF 1934
For the transition period from
to
OR
SHELLCOMPANYREPORT PURSUANT TO SECTION 13 OR15(d) OF THESECURITIES EXCHANGEACT OF 1934
Commission file number 001-37825
Talend S.A.
(Exact name of Registrant as ... |
1 | 172439318_2 | 172439318 | , nominal
value 0.08 per share Ordinary shares, nominal value 0.08 per share*
Name of each exchange on which registered The NASDAQ Stock Market LLC The NASDAQ Stock Market LLC*
* Not for trading, but only in connection with the listingof the American Depositary Shares on The NASDAQ Stock Market LLC.
Securities regis... |
1 | 172439318_3 | 172439318 | of Contents
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filin... |
1 | 172439318_b0 | 172439318 | Commitments and contingencies
Total future minimum lease payments
3,010
2021
Commitments and contingencies
Total future minimum lease payments
2,436
2022
Commitments and contingencies
Total future minimum lease payments
1,662
Thereafter
Commitments and contingencies
Total future minimum lease payments
$ 6... |
1 | 172439318_b1 | 172439318 | 400
$ 139
$ 6
Commitments and contingencies (Details) - USD
($) $ in Millions
12 Months Ended Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2015
Commitments and contingencies
Rent expense on operating leases incurred $ 3.4
$ 2.8
$ 2.3
Minimum
Commitments and contingencies
Lease expiration term
1 year
Maximum
Com... |
1 | 172442839_0 | 172442839 | ASTRAZENECA PLC
Form 20-F
Filed on 06-Mar-2018 Period 31-Dec-2017 Accession number: 0001104659-18-015257
Included Items
1. 20-F 2. EX-7.1 3. EX-8.1 4. EX-12.1 5. EX-12.2 6. EX-13.1 7. EX-15.1 8. EX-15.2 9. EX-15.3 10. EX-15.4 11. EX-15.5 12. EX-15.6 13. EX-15.7 14. XBRL (render)
UNITED STATES SECURITIES AND EXCHANG... |
1 | 172442839_1 | 172442839 | o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
to
.
OR
o SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report...................
Commission file numbe... |
1 | 172442839_2 | 172442839 | of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class American Depositary Shares, each representing one half of an Ordinary Share of 25¢ each Ordinary Shares of 25¢ each Floating Rate Notes due 2018 1.750% Notes due 2018 1.950% Notes due 2019 2... |
1 | 172442839_3 | 172442839 | Commission.
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None (Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
(Title of Class)
Indicate the number of outstanding shares of each of the issuer's classes of capital or ... |
1 | 172442839_b0 | 172442839 |
Silence Therapeutics PLC
Significant and associate holdings
Effective percentage of equity owned in associates 0.17%
AbMed Corporation 15
Significant and associate holdings
Effective percentage of equity owned in associates 18.00%
Affinita Biotech Inc. 16
Significant and associate holdings
Effective percentag... |
1 | 172442839_b1 | 172442839 | .11
Significant and associate holdings
Effective percentage of equity owned in associates 48.30%
Apollo Therapeutics LLP 7
Significant and associate holdings
Effective percentage of equity owned in associates 25.00%
C.C.Global Chemicals Company
Significant and associate holdings
Effective percentage of equity o... |
1 | 172444072_0 | 172444072 | Atlantica Yield Plc
Form 20-F
Filed on 07-Mar-2018 Period 31-Dec-2017 Accession number: 0001140361-18-012393
Included Items
1. 20-F 2. EX-8.1: EXHIBIT 8.1 3. EX-12.1: EXHIBIT 12.1 4. EX-12.2: EXHIBIT 12.2 5. EX-13.1: EXHIBIT 13.1 6. EX-15.1: EXHIBIT 15.1 7. EX-15.2: EXHIBIT 15.2 8. EX-99.1: EXHIBIT 99.1 9. XBRL (rend... |
1 | 172444072_1 | 172444072 | ANGE ACT OF 1934
For the fiscal year ended December 31, 2017 OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report__________ For the tra... |
1 | 172444072_2 | 172444072 | Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class Ordinary Shares, nominal value $0.10 per share
Name of each exchange on which registered NASDAQ Global Select Market
Securities registered or to be registered pursuant to Section 12(g) of the Act.
None
Sec... |
1 | 172444072_3 | 172444072 | 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electroni... |
1 | 172444072_b0 | 172444072 | Capital increase and other
0
0
664,120
C. Net cash provided by/(used in) financing activities
(159,599) (26,585) 845,723
Net increase/(decrease) in cash and cash equivalents
26,371
76,667
(109,880)
Cash, cash equivalents and bank overdrafts at beginning of the year 122,154 45,487
155,367
Cash and cash equiv... |
1 | 172444072_b1 | 172444072 |
Cash, cash equivalents and bank overdrafts at beginning of the year 594,811 514,712 354,154
Cash and cash equivalents at the end of the year
669,387 594,811 514,712
Parent Company [Member]
Condensed cash flowstatements [Abstract]
Cash Flow from operating activities
34,937
5,911
(15,943)
Cash Flow-investing ac... |
1 | 172457668_0 | 172457668 | Cellectis S.A.
Form 20-F
Filed on 13-Mar-2018 Period 31-Dec-2017 Accession number: 0001193125-18-080876
Included Items
1. 20-F 2. EX-4.4.1 3. EX-4.5.2 4. EX-4.6.3 5. EX-8.1 6. EX-12.1 7. EX-12.2 8. EX-13.1 9. EX-13.2 10. EX-15.1 11. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 205... |
1 | 172457668_1 | 172457668 | THE SECURITIES EXCHANGE ACT OF 1934
OR
SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
For the transition period from
to
Commission file number 001-36891
CELLECTIS S.A.
(Exact name of Registrant as specified in its cha... |
1 | 172457668_2 | 172457668 | .
Title of each class
American Depositary Shares, each representing one ordinary share, nominal value 0.05 per share
Ordinary shares, nominal value 0.05 per share*
Name of each exchange on which registered
Nasdaq Global Market
Nasdaq Global Market*
* Not for trading, but only in connection with the registration of t... |
1 | 172457668_3 | 172457668 | 1934. Yes No
Note Checking the boxabove will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sectio... |
1 | 172457668_b0 | 172457668 | , strike price | / shares Mr. Godard [Member] | Non-Employee Warrant Three [Member] Disclosure of transactions between related parties [Line Items] Number of non-employee warrants exercisable to obtain shares Number of shares to be obtained upon exercise of warrants Number of shares to be obtained upon exercise of war... |
1 | 172457668_b1 | 172457668 | [member] | License agreements [Member]
Disclosure of contingent liabilities [Line Items]
Total contractual obligations
$ 12,223
Related Parties - Additional Information (Detail)
Disclosure of transactions between related parties [Line Items] Key management personnel compensation, short-term employee benefits | $ ... |
1 | 172458688_0 | 172458688 | Uniqure N.V.
Form 10-K
Filed on 14-Mar-2018 Period 31-Dec-2017 Accession number: 0001558370-18-002042
Included Items
1. 10-K 2. EX-10.4 3. EX-10.5 4. EX-21.1 5. EX-23.1 6. EX-31.1 7. EX-31.2 8. EX-32.1 9. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 1... |
1 | 172458688_1 | 172458688 | name of Registrant as specifiedinits charter)
The Netherlands (Jurisdiction of incorporation or organization)
Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands (Address of principal executive offices) (Zip Code)
+31-20-240-6000 (Registrant's telephone number, including area code)
Securities registered pursuant ... |
1 | 172458688_2 | 172458688 | 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive D... |
1 | 172458688_3 | 172458688 | celerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
(Do not check if a smaller reporting
company)
Emerging growth company
If an emerging growth company, indicate by check mark if the re... |
1 | 172458688_b0 | 172458688 |
2,023
2021
2,023
2022
2,023
Thereafter
18,203
Total minimum lease payments
28,318
Deferred rent related to lease incentives-non current 4,288
Aggregate rent expense
Rent expense
$ 2,503 $ 2,871 $ 366
Leases - Narrative (Details) $ in Millions
1 Months Ended
12 Months Ended
Dec.
01,
2017
May 31, 201... |
1 | 172458688_b1 | 172458688 | 3,979
2021
4,032
2022
4,086
Thereafter
21,030
Total minimum lease payments
40,925
Deferred rent related to lease incentives-non current 9,114
Deferred rent related to lease incentives-current 737
Aggregate rent expense
Rent expense
3,606
$ 3,974 $ 1,469
Lexington
Minimum lease payments
2018
1,849
201... |
1 | 172461039_0 | 172461039 | British American Tobacco P.L.C.
Form 20-F
Filed on 15-Mar-2018 Period 31-Dec-2017 Accession number: 0001193125-18-083410
Included Items
1. 20-F 2. EX-2.4 3. EX-2.5 4. EX-2.7 5. EX-4.12 6. EX-4.13 7. EX-4.14 8. EX-4.15 9. EX-4.16 10. EX-4.17 11. EX-4.18 12. EX-4.19 13. EX-4.20 14. EX-4.21 15. EX-11 16. EX-12 17. EX-13... |
1 | 172461039_1 | 172461039 | SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended 31 December 2017
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring... |
1 | 172461039_2 | 172461039 | mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class
American Depositary Shares (evidenced by American Depositary Receipts) each representing one Ordinary Share
Ordinary Shares, nominal value 25 pence per... |
1 | 172461039_3 | 172461039 |
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes No
Note Checking the boxabove will not relieve any registrant required to file reports pursuant to Section 13 or 1... |
1 | 172461039_b0 | 172461039 | December
2
RJRTH, Subsidiary guarantor (LB & RB)
Disclosure Of Condensed Consolidating Financial Information [Line Items]
Net cash (used in)/generated from operating activities
(11)
Net cash (used in)/generated from investing activities
1
Net cash (used in)/generated from financing activities
10
All other co... |
1 | 172461039_b1 | 172461039 | LB)
Disclosure Of Condensed Consolidating Financial Information [Line Items]
Net cash (used in)/generated from operating activities
(1,860)
Net cash (used in)/generated from investing activities
(88)
Net cash (used in)/generated from financing activities
1,950
Net cash flows (used in)/generated fromoperating, i... |
1 | 172461154_0 | 172461154 | Adaptimmune Therapeutics PLC
Form 10-K
Filed on 15-Mar-2018 Period 31-Dec-2017 Accession number: 0001104659-18-017694
Included Items
1. 10-K 2. EX-10.1 3. EX-10.2 4. EX-10.3 5. EX-10.4 6. EX-10.5 7. EX-10.6 8. EX-23.1 9. EX-31.1 10. EX-31.2 11. EX-32.1 12. EX-32.2 13. XBRL (render)
Table of Contents
UNITED STATES ... |
1 | 172461154_1 | 172461154 | IMMUNE THERAPEUTICS PLC
(Exact name of Registrant as specified in its charter)
England and Wales (State or other jurisdiction of incorporation or organization)
Not Applicable (I.R.S. Employer Identification No.)
60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX
United Kingdom (Address of principal execut... |
1 | 172461154_2 | 172461154 |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requireme... |
1 | 172461154_3 | 172461154 | registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large... |
1 | 172461154_b0 | 172461154 | Income taxes - Net Operating Loss and Expenditure Credit
Carryforwards (Details) USD ($)
$ in Thousands
6 Months Ended
12 Months Ended
Dec. 31, 2015 Dec. 31, 2017 Dec. 31, 2016 Jun. 30, 2015
Net Operating Loss and Expenditure Credit Carryforwards
Net operating loss
$ (26,410) $ (80,661) $ (72,799) $ (24,641)
In... |
1 | 172461154_b1 | 172461154 | age on taxable profit
50.00%
50.00%
Operating Loss Carryforwards And Tax Credit Carryforward Annual Allowance | £
£ 5
Her Majesty's Revenue and Customs (HMRC)
Income taxes
Tax rate (as a percent)
19.00%
20.00% 19.25% 19.25% 20.00% 20.75%
Tax rate, deferred taxes (as a percent)
17.00%
Her Majesty's Revenue a... |
1 | 172464970_0 | 172464970 | Nabriva Therapeutics Plc
Form 10-K
Filed on 16-Mar-2018 Period 31-Dec-2017 Accession number: 0001047469-18-001768
Included Items
1. 10-K 2. EX-10.16 3. EX-10.17 4. EX-10.18 5. EX-21.1 6. EX-23.1 7. EX-23.2 8. EX-31.1 9. EX-31.2 10. EX-32.1 11. EX-32.2 12. XBRL (render)
Use these links to rapidly review the document... |
1 | 172464970_1 | 172464970 | SECURITIES EXCHANGE ACT OF 1934
For the transition period from
to
Commission file number 001-37558
Nabriva Therapeutics plc
(Exact name of registrant as specified in its charter)
Ireland (State or jurisdiction of organization)
Not applicable (I.R.S. Employer Identification No.)
25-28 North Wall Quay IFSC, Dubli... |
1 | 172464970_2 | 172464970 | 13 or Section 15(d) of the Act. Yes o No ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (... |
1 | 172464970_3 | 172464970 | check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the... |
1 | 172464970_b0 | 172464970 | from operations Other income (expense) Income tax (expense) benefit Net loss
Basic and diluted loss per share Restatement Adjustment | Redomiciliation Transaction Selected Quarterly Financial Information (Unaudited) Basic and diluted loss per share
3 Months Ended
12 Months Ended
Dec. 31, Sep. 30, Jun. 30, Mar. 31, ... |
1 | 172464970_b1 | 172464970 | Therafter Other contractual commitments Total 2018 Future minimum contractual obligations and commitments Total 2018 2019 2020 2021 2022 Therafter Lease Agreement, Business and Research Premises Lease Arrangements Term of the lease agreement, under which it can only be terminated under certain conditions Lease Agreeme... |
1 | 172465395_0 | 172465395 | DBV Technologies S.A.
Form 20-F
Filed on 16-Mar-2018 Period 31-Dec-2017 Accession number: 0001193125-18-085953
Included Items
1. 20-F 2. EX-1.1 3. EX-4.14 4. EX-4.15 5. EX-8.1 6. EX-12.1 7. EX-12.2 8. EX-13.1 9. EX-13.2 10. EX-15.1 11. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSIO... |
1 | 172465395_1 | 172465395 | ANGE ACT OF 1934
For the transition period from to OR
SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report Commission File Number 001-36697
DBV TECHNOLOGIES S.A.
(Exact name of registrant as specified in its charter and translatio... |
1 | 172465395_2 | 172465395 | 10 per share
Ordinary shares, nominal value 0.10 per share*
* Not for trading, but only in connection with the registration of the American Depositary Shares.
Name of each exchange on which registered
The Nasdaq Stock Market LLC
The Nasdaq Stock Market LLC*
Securities registered or to be registered pursuant to Sectio... |
1 | 172465395_3 | 172465395 | has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by ch... |
1 | 172465395_b0 | 172465395 | ) (44,674)
Adjusted weighted average number of outstanding shares 24,757,176 24,454,850 21,522,342
Basic / Diluted earnings per share (/share)
(5.97) (4.68) (2.08)
Management of Financial Risks - Additional
Information (Detail) - EUR ()
in Thousands
12 Months Ended Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2015 D... |
1 | 172465395_b1 | 172465395 | Payable
689
767
674
Pension obligation [member]
Disclosure of amount payables to related parties [Line Items]
Amounts Payable
402
342
233
Earnings Per Share Additional Information
(Detail) - shares
12 Months Ended Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2015
Earnings per share [line items]
Description of... |
1 | 172465729_0 | 172465729 | AVADEL PHARMACEUTICALS PLC
Form 10-K
Filed on 16-Mar-2018 Period 31-Dec-2017 Accession number: 0001012477-18-000008
Included Items
1. 10-K 2. EX-10.43: EXHIBIT 10.43 3. EX-10.44: EXHIBIT 10.44 4. EX-10.45: EXHIBIT 10.45 5. EX-10.46: EXHIBIT 10.46 6. EX-21.1: EXHIBIT 21.1 7. EX-23.1: EXHIBIT 23.1 8. EX-23.2: EXHIBIT 2... |
1 | 172465729_1 | 172465729 | -K
ý ANNUAL REPORTPURSUANTTO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACTOF 1934 For the fiscal year ended December 31, 2017
Commission file number: 000-28508
AVADEL PHARMACEUTICALS PLC
(Exact name of registrant as specified in its charter)
Ireland State or other jurisdiction of incorporation or organization
98-... |
1 | 172465729_2 | 172465729 | inary
** Nominal value $0.01 per share. Not for trading, but only in connection with the listing of American Depositary Shares.
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨... |
1 | 172465729_3 | 172465729 | (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, ... |
1 | 172465729_b0 | 172465729 |
$ 15,263,000
Research and development reimbursement, in excess of
$ 1,000,000
FSC | Discontinued operations, disposed
of by sale | 2016 MIPA | Subsequent event
Subsequent Event [Line Items]
Percentage of royalty payable on net sales
15.00%
Royalty payable on net sales, maximum
$
10,300,000
Eclat Pharmaceuti... |
1 | 172465729_b1 | 172465729 | shares
$ 8.99
ADS option price, in dollars per share | $ / shares
$ 10.79
ADS premium percentage
20.00%
Exchangeable Senior Notes Due 2023 |
Subsequent event
Subsequent Event [Line Items]
Aggregate principal amount
$ 125,000,000
Interest rate
4.50%
Option to increase aggregate principal $
amount
18,750,... |
1 | 172468498_0 | 172468498 | LUXFER HOLDINGS PLC
Form 20-F
Filed on 19-Mar-2018 Period 31-Dec-2017 Accession number: 0001096056-18-000011
Included Items
1. 20-F 2. EX-2.4: EXHIBIT 2.4 3. EX-4.2: EXHIBIT 4.2 4. EX-12.1: EXHIBIT 12.1 5. EX-12.2: EXHIBIT 12.2 6. EX-13.1: EXHIBIT 13.1 7. EX-13.2: EXHIBIT 13.2 8. EX-15.1: EXHIBIT 15.1 9. XBRL (render... |
1 | 172468498_1 | 172468498 | ) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
o
SHELL COMPANY REPORT PURSUANT TO SEC... |
1 | 172468498_2 | 172468498 |
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class Ordinary Shares, nominal value £0.50 each
Name of each exchange on which registered New York Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which th... |
1 | 172468498_3 | 172468498 | registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No... |
1 | 172468498_b0 | 172468498 | venturer | Amount from debt investment
Disclosure of transactions between related parties [line items]
Amounts receivable, related party transactions
4,700,000 3,800,000
Sub161 Pty Limited | Associates
Disclosure of transactions between related parties [line items]
Sales to related party
$ 0
$ 100,000
Amounts... |
1 | 172468498_b1 | 172468498 | EL Co. Limited | Joint ventures where entity is venturer
Disclosure of transactions between related parties [line items]
Investment ownership percentage
50.00%
Sales to related party
$ 1,200,000 800,000
Luxfer Holdings NA, LLC | Joint ventures where entity is venturer
Disclosure of transactions between related p... |
1 | 172473466_0 | 172473466 | Nucana Plc
Form 20-F
Filed on 22-Mar-2018 Period 31-Dec-2017 Accession number: 0001564590-18-006509
Included Items
1. 20-F 2. EX-2.1: EX-2.1 DEPOSIT AGREEMENT 3. EX-4.1: EX-4.1 REGISTRATION RIGHTS
AGREEMENT 4. EX-4.10: EX-4.10 RESEARCH AND
COLLABORATION AGREEMENT 5. EX-4.11: EX-4.11 LEASE 6. EX-12.1: EX-12.1 CEO CERT... |
1 | 172473466_1 | 172473466 | CHANGECOMMISSION
WASHINGTON, D.C. 20549
FORM 20-F
REGISTRATION STATEMENTPURSUANTTO SECTION 12(b) OR (g) OF THESECURITIES EXCHANGEACTOF 1934
OR
ANNUAL REPORTPURSUANTTO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACTOF 1934
For the fiscal year ended December 31, 2017
OR
TRANSITION REPORTPURSUANTTO SECTION 1... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.